Join to View Full Profile
10121 Pine AveTruckee, CA 96161
Phone+1 530-582-6450
Dr. Semrad is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Thomas Semrad, MD, is an oncologist based in Truckee, CA. He completed his fellowship in Hematology and Medical Oncology and his residency in Internal Medicine at the University of California Davis Health. Dr. Semrad is a graduate of Rush Medical College of Rush University Medical Center in 2004. He is a prolific author and has published numerous articles in well-regarded medical journals, focusing on various aspects of oncology, and has led multiple clinical trials. He received the CMS Meaningful Use Stage 1 Certification in 2012.
Education & Training
University of California Davis HealthFellowship, Hematology and Medical Oncology, 2007 - 2010- University of California Davis HealthResidency, Internal Medicine, 2004 - 2007
Rush Medical College of Rush University Medical CenterClass of 2004
Certifications & Licensure
CA State Medical License 2005 - 2027
NV State Medical License 2023 - 2027
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
- Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer Start of enrollment: 2010 Sep 09
- S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer Start of enrollment: 2012 Feb 01
Publications & Presentations
PubMed
- Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update.Manish A Shah, Erin B Kennedy, Dana Deighton, Minaxi Jhawer, Kunal C Kadakia
Journal of Clinical Oncology. 2026-04-20 - 4 citationsA phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors.Sonia M Abuzakhm, Vineeth Sukrithan, Briant Fruth, Rui Qin, Jonathan Strosberg
Endocrine-Related Cancer. 2023-11-01 - 141 citationsImmunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.Manish A Shah, Erin B Kennedy, Ashley E Alarcon-Rozas, Thierry Alcindor, Angela N Bartley
Journal of Clinical Oncology. 2023-03-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
